Dataset Information


An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

ABSTRACT: OBJECTIVES:Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). METHODS:Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab. Cycles 7-12 included cetuximab/bevacizumab with gemcitabine. Cycles were 2 weeks. Frequency of specific toxicities was summarized for each treatment arm at two times during the study, after chemotherapy but prior to chemoradiation and after all therapy. RESULTS:A total of 127 patients were randomized (A, n = 65; B, n = 62). Prior to chemoradiation, the overall rate for toxicities of interest was 10% for arm A and 2% for arm B. After all therapy, the overall rates for toxicities of interest were 30 and 25% for arms A and B, respectively. Overall median OS and DFS were 17 and 11 months, respectively, which is not a significant improvement over expected survival rates for historical controls. CONCLUSIONS:Both treatments were tolerable with manageable toxicities, and were safe enough for a phase III trial had this been indicated.


PROVIDER: S-EPMC5828967 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4474505 | BioStudies
2013-01-01 | S-EPMC3977741 | BioStudies
2016-01-01 | S-EPMC4740006 | BioStudies
1000-01-01 | S-EPMC5237801 | BioStudies
2010-01-01 | S-EPMC2988636 | BioStudies
2013-01-01 | S-EPMC4072123 | BioStudies
1000-01-01 | S-EPMC5029622 | BioStudies
1000-01-01 | S-EPMC4319643 | BioStudies
2018-01-01 | S-EPMC6311014 | BioStudies
2012-01-01 | S-EPMC3397785 | BioStudies